Meningococcal septic shock has a rapid onset and characteristic skin hemorrhages that allow bedside diagnosis. Initial plasma endotoxin levels are high and correlate closely with clinical outcome. In a double-blind, randomized, placebo-controlled trial (planned, n Å 270; actual, n Å 269), we compared the effectiveness of HA-1A (6 mg/kg of body weight iv; maximum, 100 mg), a human monoclonal antibody to endotoxin, and placebo in reducing the 28-day all-cause mortality rate among children with a presumptive clinical diagnosis of meningococcal septic shock. Treatment groups were well balanced for baseline characteristics and prespecified prognostic variables. In this trial no significant benefit of HA-1A could be demonstrated. The 28-day mortality rates in the intention-to-treat analysis were as follows: placebo, 28%; HA-1A, 18%; reduction in mortality, 33% (P Å .11, per Fisher's exact test, two-tailed; odds ratio Å 0.59; 95% confidence interval for the difference, 0.31 -1.05). All patients tolerated HA-1A well, and no antibodies to HA-1A were detected.
Fulminant meningococcal septic shock (MSS) remains a cemia) found that antiserum to J5 did not significantly alter the highly fatal disease despite the continuing advances in supportclinical course or mortality [9] . ive care [1] . Endotoxin, the lipopolysaccharide (LPS) compoSeveral randomized clinical trials have been performed to nent of the gram-negative bacterial cell wall, is considered to study the efficacy of two monoclonal antibodies: E5, a murine be the most important bacterial factor in the pathogenesis of IgM, and HA-1A, a human IgM. In the first E5 trial, antibody systemic meningococcal infections. In patients with Neisseria treatment appeared to augment the survival rate among patients meningitidis bacteremia, initial plasma endotoxin levels correwith gram-negative sepsis who were not in shock [10] . This late closely with morbidity and mortality, and these levels are finding was not confirmed in a second study, although a trend often several logs higher than commonly observed in other toward improved survival rates among treated patients with forms of gram-negative septicemia [2 -4] . The endotoxin levels major organ failure was observed [11] . In both trials the subare, furthermore, quantitatively associated with key mediators group effects were not shown to differ in magnitude from the contributing to the host's inflammatory response [4, 5] . The effect in the remainder of the patients in the trial. toxic moiety of endotoxin is lipid A, which is relatively well Two large clinical trials with HA-1A have been published. conserved among different gram-negative bacteria [6, 7] .
The first study showed no overall benefit of HA-1A, but sigThe assumed central role of endotoxin in gram-negative sepnificant improvement in the survival rate was observed in a sis has led to the investigation of different antibodies directed subgroup of patients with gram-negative bacteremia and shock against the lipid A moiety of endotoxin in several clinical [12] . Again, the effect in this subgroup did not differ signifitrials. Increased survival has been demonstrated among gramcantly from the effect in the other subgroups. A second trial negative bacteremic patients with septic shock treated with sera that also showed no overall clinical benefit of HA-1A was obtained from individuals immunized with injections of an discontinued at the first interim analysis because of a nonsigEscherichia coli mutant (J5) [8] ; however, a study of children nificant survival disadvantage among patients without gramwith severe infectious purpura (mainly due to meningococnegative bacteremia [13] . Although these results do not provide clear evidence of increased survival among patients with sepsis, they do not preclude the possibility that anti-endotoxin therapy might be beneficial for certain patients with gram-negative An independent Safety and Efficacy Monitoring Committee agreed to provide aggressive, supportive care and if the child (1) had petechiae (pinpoint hemorrhage, õ2 mm) and/or purassessed the results of the trial. The committee had the authority to recommend early termination of the trial if the difference pura (palpable or nonpalpable hemorrhage(s), §2 mm), (2) was older than 3 months but less than 18 years, and (3) had in survival reached significance or if serious or unexplained side effects occurred. The analyses were performed on the persistent hypotension requiring aggressive therapy within 12 hours before enrollment. Hypotension was defined as systolic ''intention-to-treat'' population. Secondary analyses included covariate-adjusted logistic regressions, subgroup analyses of blood pressure of õ75 mm Hg for children aged 3 -12 months, õ80 mm Hg for children aged 1 -5 years, õ85 mm Hg for the primary endpoint, and Kaplan-Meier survival analyses [16] comparing the placebo and HA-1A groups. Survival children aged 6 -12 years, and õ100 mm Hg for those aged ú12 years.
curves were tested with log-rank tests. The data were fit with use of a series of logistic regression models with 28-day mor-A nonhypotensive child was eligible if there was evidence of systemic toxicity or poor end-organ perfusion, defined by tality as the outcome. Treatment group and several baseline covariates including baseline log (endotoxin) were used as at least two of the following criteria, within 24 hours of enrollment: (1) unexplained metabolic acidosis, defined as a pH of predictor variables. As a part of the investigation of the properties of HA-1A, £7.3, a base deficit of §5, or a plasma lactate level of ú2 mmol/L; (2) arterial hypoxia, defined by a PO 2 (partial pressure the following subgroups were analyzed: treated patients only, treated patients with a documented non -N. meningitidis cause of oxygen) of £75 mm Hg, a PO 2 /FIO 2 (fraction of inspired oxygen) ratio of õ250, or TCO 2 (total carbon dioxide, saturated) of their initial presentation, treated patients with a positive N. meningitidis culture or a positive antigen test, treated paof £96% in patients without overt pulmonary disease as the cause; (3) acute renal failure, defined as oliguria with a urine tients with at least one N. meningitidis -positive culture (of blood, CSF, or a skin aspirate), and treated patients with at output of õ0.5 mL/(kgrh) for at least 1 hour despite acute fluid volume loading or evidence of adequate intravascular least one N. meningitidis -positive blood culture. The primary efficacy analyses were performed on each of these subgroups, volume and no renal disease; and (4) sudden deterioration of baseline mental status. Children participating in other investigaas well as on 56-day mortality. Fisher's exact tests were used; because no interim analyses were performed on the 56-day tional drug trials, those who had previously received a monoclonal antibody or intravenous immunoglobulin, pregnant girls, endpoint, the significance level was set at 0.05. Other nonmortality endpoints included the event rate for the and children for whom there was a ''do not resuscitate'' order were excluded.
following sequelae categories separately and as a composite: amputation, skin grafts, severe neurological sequelae, deafness, The institutional review boards and local research ethics committees of all participating centers approved the study problindness, and pericarditis/myocarditis. The analytic plan identified several secondary variables to be analyzed in the primary tocol before enrollment began. Parents or legal guardians gave written consent after receiving oral and written information.
population and the subgroups of interest, such as change in hematologic and biochemical parameters from baseline, includThe primary objective of the trial was to study the efficacy of a single dose of HA-1A (6 mg/kg body weight [bw] iv; ing endotoxin level. Statistical analyses were performed with use of SAS software, version 6.08 [17] . Power calculations maximum, 100 mg) compared with that of placebo in reducing the 28-day all-cause mortality rate among children (aged ú3
were performed with use of PASS 6.0 [18] . months and õ18 years) admitted with a presumptive clinical diagnosis of MSS and in patient subgroups defined by N. menAssignment ingitidis culture and antigen status. The secondary objective was to assess the safety of HA-1A.
Children were randomly assigned by center in blocks of two or four to receive either HA-1A or placebo. Treatment was The study was a double-blind, randomized, placebo-controlled, multicenter, fixed-sample-size trial with planned inassigned at the individual patient level. Within each center each child received a consecutive enrollment number when terim analysis after enrollment of 1 / 3 and 2 / 3 of the total number of patients (n Å 270). Epidemiological data predicted a 30% eligibility for the study was confirmed. Twenty-six centers with pediatric intensive care facilities in The Netherlands, Great mortality rate in the placebo group, and the expected 28-day all-cause mortality rates in the placebo and HA-1A groups were Britain, France, Spain, and Norway enrolled patients. An independent coordinating center created a treatment-allo-30% and 15%, respectively. The calculated sample size of 270 patients provided 80% power for a two-sided a Å 0.05 test of cation code for each site, labeled vials, monitored compliance with the blinding procedures, audited the data for consistency antigen test and also on day 14 for patients with negative cultures. and accuracy, and conducted the interim analysis. The full randomization codes remained concealed until completion of Shortly before infusion a clinical evaluation was performed. Information was collected regarding the onset of symptoms, the primary analysis.
onset of petechiae/ecchymoses, first treatment with antibiotics, and transfer from another hospital. The medical history,
Treatment
including known risk factors for meningococcal disease, was obtained. A baseline physical examination was performed, HA-1A (Centoxin; Centocor, Malvern, PA) is a human IgM and a detailed description of the skin hemorrhages was remonoclonal antibody that binds to the lipid A domain of endocorded. Vital signs (heart rate, blood pressure, respiratory toxin and is produced by the stable heteromyeloma cell line rate, and temperature) were recorded before, in the middle A6(H4C5), developed by Teng et al. [19] . This hybridoma was of, and at the end of infusion of the study material; frequently created by fusion of a murine-human heteromyeloma line with during the first 24 hours after infusion; and then on days 3, splenic B lymphocytes sensitized in vivo by immunization with 7, 10, and 14. Routine hematologic and clinical chemistry killed E. coli J5 cells and subsequently transformed in vitro tests were performed before infusion and on days 1, 3, 5, 7, by Epstein-Barr virus. The clone produces only human IgM and 14 or until the values were normal. Blood samples for antibody and is free of Epstein-Barr viral genome and of detectdetermination of endotoxin levels were collected preinfusion able murine viruses. In experimental models, HA-1A protects (within 90 minutes after admission) and then 12 and 24 hours animals against endotoxemia and development of the dermal postinfusion from the first 123 patients. Samples for HA-1A Shwartzman reaction [19, 20] . HA-1A has been shown to bind antibody assay were collected before and approximately 28 N. meningitidis LPS [21] . Clinical studies reported no severe and 56 days after infusion. side effects; antibodies to HA-1A were not detected in any patient.
Patients enrolled in this trial were randomly assigned to Endotoxin Assay receive either HA-1A (6 mg/kg bw [1.2 mL/kg bw], with a For determination of endotoxin levels, blood was collected maximum of 100 mg iv, diluted with 3.5 g of albumin) or an in pyrogen-free tubes (Falcon 2063; Becton Dickinson, Linidentical-appearing placebo consisting of 3.5 g of human serum coln Park, NJ) and immediately immersed in melting ice. Pyroalbumin. This material was injected into normal saline (3.0 gen-free heparin (Organon Teknika BV, Boxtel, the NethermL/kg bw; maximum, 50 mL). The final solution was infused lands; final concentration, 50 immunizing units per mL of over a period of 15 -30 minutes through an iv line through blood) was used for anticoagulation. After centrifugation at which no other drug was currently being infused. The study 190g at 4ЊC for 10 minutes, platelet-rich plasma was collected, drug was administered as soon as inclusion criteria were met immediately frozen, and stored at 020ЊC. The endotoxin conand informed consent obtained. Decisions regarding the use of tent was determined by a chromogenic Limulus amebocyte antibiotics, steroids, iv fluids, inotropes, and cardiovascular and assay (Coatest Endotoxin; Chromogenix AB, Mölndal, Swerespiratory support were made at the participating centers and den). The method has a detection limit in blood of 0.036 were not dictated by the study protocol.
endotoxin units (EU)/mL. Each sample was assayed in duplicate, and the results were expressed as the mean.
Evaluation of the Patients
Results The patients were followed for 56 days or until death. At enrollment, three meningococcal disease severity scores were Study Population calculated: the Glasgow meningococcal septicemia prognostic score (including hypotension, defined according to age; T delta In a 5-year period a total of 269 children were enrolled in the study. Nine centers enrolled between 11 and 57 patients [central temperature minus peripheral temperature]; modified coma scale; presence of meningitis; deterioration in last hour; each. Of these centers, 2 in the Netherlands, 3 in Great Britain, and 2 in France enrolled 83% of all patients; the remaining 17 extensive rash; and base deficit) [22] , the Leclerc score (including age, presence of meningitis, leukocyte count, platelet count, centers enrolled between 1 and 6 patients each. Approximately 55 patients were enrolled each year; most patients were admitand serum potassium level) [23] , and the Stiehm-Damrosch score (including hypotension, recent onset of petechiae, leukoted to the hospital in the first and last quarters of the year. Two randomized patients did not receive the study drug. One was cyte count, erythrocyte sedimentation rate, and presence of leukocytes in CSF) [24] .
a patient who was randomized to the HA-1A group but was not infused because of lack of parental consent. The second For every patient a blood culture was performed on admission. If meningitis was suspected, CSF was obtained for culture.
patient, who was randomized to the placebo group, died before the placebo could be administered. Of the 267 treated patients, For some patients a skin aspirate from a hemorrhagic spot was cultured. Blood was drawn on day 0 for an N. meningitidis 137 received placebo and 130 received HA-1A.
/ 9c64$$ap02 03-15-99 09:24:04 cidal UC: CID test, and regardless of the source of the bacteria (blood [or blood and other sources], CSF, or aspirates). The difference between the placebo and HA-1A treatment groups was not showed a mortality of 38/138 (28%) among the placebo-treated statistically significant in any of these patient subgroups. The patients and 24/131 (18%) in the HA-1A-treated group, re-28-day mortality rate for patients with culture-or antigensulting in an observed 33% reduction in mortality (P Å .11, proven MSS was 24% among patients receiving placebo and per Fisher's exact test, two-tailed; OR Å 0.59; 95% CI for the 19% among those who received HA-1A (P Å .49). HA-1A difference, 0.31 -1.05). No relationship between the relative treatment was not associated with increased mortality in the risk (HA-1A vs. placebo) and the size of the treatment site group with a non-N. meningitidis bacterial etiology (one of two could be demonstrated, and pooled estimates for the small patients died in each treatment group). In the group without treatment sites were almost the same as the pooled estimates documentation of meningococcal etiology, the observed morfor the large sites (data not shown).
tality was lower for the HA-1A recipients (5/34, vs. 11/30 for All-cause mortality for patients who were randomized and placebo recipients). received the study agent was determined on days 28 and 56; the results are presented in table 3. By 28 days after infusion Sequelae there were 37 deaths among the 137 placebo recipients (27%) and 24 deaths among the 130 recipients of HA-1A (18%).
Sequelae at day 28 included amputation of extremities, skin This 32% reduction in mortality observed on day 28 grafts, presence of neurological sequelae (seizures after day (P Å .08) was evident as early as the first 48 hours after 7, cranial nerve palsies, hemiplegia, hydrocephalus, persistent treatment. Most deaths (82%) occurred within the first 2 days alteration of level of consciousness), deafness, blindness, and after randomization. The reduction in mortality was maintained through 56 days, with a 29% overall decrease in deaths from the 27% (37/136) in the placebo group to the 19% The overall rates were 9.5% in the placebo group and 9.2% in with the study agent was hypotension, reported in four patients reasonably related to the study agent; six (4.4%) occurred in the placebo group and four (3.1%) in the HA-1A group.
Discussion
exceeded that of patients given placebo (37%) by an amount greater than prespecified in the safety stopping rule. The overall In this randomized, placebo-controlled, sequential trial, no mortality was 33% among patients with gram-negative bacterstatistically significant benefit of HA-1A, a human monoclonal emia who received HA-1A and 32% in the placebo group. antibody to endotoxin, could be demonstrated in terms of the Several factors can account for the fact that the study showed 28-day mortality for children with MSS. Intention-to-treat anala lack of overall clinical benefit of HA-1A. First, patients dying ysis showed mortality rates of 28% in the placebo group and of endotoxemia are most likely to benefit from endotoxin-18% in the HA-1A group, for a 33% absolute reduction in antibody therapy, but until now it has been impossible to clinimortality (P Å .11). The two treatment groups were well cally identify patients with gram-negative bacteremia and/or matched with respect to demographics, risk factors at presentaendotoxemia in an early stage of the sepsis syndrome. Consetion, and therapy given for the sepsis syndrome.
quently, these trials in septic patients have shown multiple At present no single endotoxin-antibody therapeutic strategy causative microorganisms (gram-negative and gram-positive has been shown to improve the clinical outcome for patients bacteria, fungi, etc.) and large differences in the incidence of with sepsis syndrome or septic shock. Nevertheless, in some endotoxemia. Second, the patient populations are often heteroclinical trials certain subgroups seemed to benefit from endogeneous, with multiple risk factors and various concurrent untoxin-antibody therapy. HA-1A has been studied in two large derlying conditions such as cancer, diabetes, trauma, and surgitrials. In a multicenter, double-blind, randomized, placebo-concal procedures. The approach of attempting downregulation of trolled phase III trial that included 543 patients with sepsis, no the endotoxin-induced pathway of gram-negative sepsis may overall benefit of HA-1A could be demonstrated [12] ; however, in fact be valid, but perhaps inadequacies in clinical trial design among 102 patients with gram-negative bacteremia and shock, and/or the anti-endotoxin agents tested have obscured the findthe 28-day all-cause mortality rate was significantly reduced ings. Further clinical trials should aim to identify a restricted from 56% among patients receiving placebo to 33% among and homogenous patient population that might benefit from those receiving HA-1A. These results were not confirmed in a therapy. second study, a large, group-sequential, placebo-controlled trial MSS is a unique model for the study of sepsis because it that enrolled 2,199 patients, of whom 621 (28%) had gramis a fulminant disease with a specific cause and is rapidly negative bacteremia [13] .
recognizable, owing to its characteristic skin hemorrhages [25, This latter trial was discontinued at the first interim analysis 26]. Moreover, most patients have no underlying disease or because the all-cause mortality rate for patients treated with HA-1A who did not have gram-negative bacteremia (42%) specific risk factor present. The high initial endotoxin levels / 9c64$$ap02 03-15-99 09:24:04 cidal UC: CID
